Equities
Health CareHealth Care Providers
  • Price (MXN)8,442.11
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change+1.10%
  • Beta--
Data delayed at least 20 minutes, as of Mar 12 2024 17:12 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Elevance Health, Inc. is a health company. It operates as a health insurer in the United States. The Company operates through four segments: Health Benefit, CarelonRx, Carelon Services, and Corporate & Other. The Health Benefits segment offers a comprehensive suite of health plans and services to Individual, employer group risk-based, employer group fee-based, BlueCard, Medicare, Medicaid and federal employees health benefits (FEHB) program members. The CarelonRx segment includes its pharmacy business. CarelonRx markets and offers pharmacy services to affiliated health plan customers, as well as to external customers outside of the health plans. It also offers infusible and injectable therapies. Carelon Services offers healthcare-related services and capabilities to internal and external customers including integrated care delivery, behavioral health, palliative care, utilization management, payment integrity services and subrogation services, as well as health and wellness programs.

  • Revenue in USD (TTM)171.34bn
  • Net income in USD5.99bn
  • Incorporated2001
  • Employees104.90k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ELV:NYQ since
announced
Transaction
value
Paragon Healthcare IncDeal completed04 Jan 202404 Jan 2024Deal completed8.14%--
Data delayed at least 15 minutes, as of Mar 28 2024 14:35 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.